Annovis Bio Unveils New Clinical Data on Buntanetap at CTAD 2025

+2.23%

Annovis Bio

ANVS

3.66

+2.23%

Annovis Bio Inc. has announced two upcoming presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, scheduled for December 1-4, 2025, in San Diego, California. The first presentation will address amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson's disease dementia patients. The second presentation will discuss a double 6/18-month Phase 3 study designed to evaluate the symptomatic and potential disease-modifying efficacy of buntanetap in treating Alzheimer's disease. The results from these studies will be presented at the CTAD conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9590780-en) on November 24, 2025, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.